Abstract:PURPOSE: This study aimed to develop a population pharmacokinetic (PPK) model for meropenem to optimize dosing regimens for critically ill patients with pulmonary infection.PATIENTS AND METHODS: This prospective PPK study of meropenem was conducted on a pooled dataset of 236 blood samples obtained from 48 patients with pulmonary infection in the intensive care unit. Meropenem plasma concentrations were measured by a validated high-performance liquid chromatography-tandem mass spectrometry method, and the data were analyzed using NONMEM. The effect of covariates on meropenem pharmacokinetics was investigated. The probability of target attainment (PTA) to achieve the target of 100% fT>MIC at the proposed dosage regimens were investigated by Monte Carlo simulations.RESULTS: A two-compartment model adequately described the data with estimated glomerular filtration rate (eGFR) as a covariate significantly associated with the clearance (CL) from the central compartment. The typical value of CL was 7.48 L/h, with an eGFR adjustment factor of 0.0103 mL•1.73 m2/min, and the typical values of volume of the central compartment (V1), peripheral compartmental clearance (Q), and volume of the peripheral compartment (V2) were 15.9 L, 15.8 L/h, and 14.8 L, respectively. The goodness-of-fit plots, normalized prediction distribution error, and visual predictive checks showed good fitting and predictability of the final PPK model. When eGFR was >90 mL/min/1.73 m2, and there was a short duration of infusion (<60min), it was difficult for the probability target attainment (PTA) to reach >90% for MIC ≥ 2. Continuous infusion and frequent administration were necessary to achieve the target of 100% fT>MIC for critically ill patients with pulmonary infection.CONCLUSION: To achieve the optimal PTA, meropenem must be administered by frequent administration or continuously by an intravenous infusion. Our findings provide important information to optimize the meropenem regime in critically ill patients with pulmonary infection depending on eGFR values.

Determination of meropenem by HPLC and study of pharmacokinetics in Chinese elder patients in ICU

Pharmacokinetics and Pharmacodynamics of Meropenem in Elderly Chinese with Lower Respiratory Tract Infections

Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection

Determination of Tigecycline in Human Plasma by LC-MS/MS and Its Application to Population Pharmacokinetics Study in Chinese Patients with Hospital-Acquired Pneumonia.

Pharmacokinetic/Pharmacodynamic Analysis Of Imipenem In Plasma And Peritoneal Liquid In Chinese Patients With Perforated Upper Gastrointestinal Tract

Determination of Free and Total Meropenem Levels in Human Plasma and Its Application for the Consistency Evaluation of Generic Drugs

Pharmacokinetics of Meropenem Single Dose Intravenous in Healthy Volunteers

A simple HPLC-MS/MS method for the determination of polymyxin B in human plasma and its application in the pharmacokinetic study in elderly patients infected with multidrug-resistant Gram-negative bacteria

Cohort Study of Therapeutic Drug Monitoring on Meropenem in Intensive Care Unit Patients

Determination of biapenem in human plasma and urine by a simple HPLC method for its pharmacokinetics study

Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia

Predictors for non-attainment of meropenem target concentrations when treating infections in critically ill patients

Meropenem Dosing Based on a Population Pharmacokinetic–Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract

Determination of plasma imipenem in critically ill patients by HPLC and research on PK/PD targeted attainment

Determination of Imipenem, Meropenem, Panipenem, Faropenem Concentrations in Human Plasma by HPLC

Changes of PK/PD of Meropenem in patients with abdominal septic shock and exploration of clinical rational administration plan: a prospective exploratory study

A Fast and High-Sensitivity Liquid Chromatography-Tandem Mass Spectrometry Method Combined with in Vivo Microdialysis for Quantification of Meropenem in Rabbits with Sepsis under the Simultaneous Infusion of Total Parenteral Nutrition: Application to a Pharmacokinetic Study.

Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients

Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study

Clinical Evaluation of Extending Administration Time of Meropenem in Treatment of Bacterial Infections in Surgical Intensive Care Unit

Determination of teicoplanin serum concentration in critically ill patients